Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06387667 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Study sites: 0 to 1
    v4
  2. Primary completion date: Dec 1, 2025 to Dec 1, 2026
    • Start date: Dec 1, 2024 to Dec 1, 2025
    • Study completion date: Jun 1, 2026 to Jun 1, 2027
    v3
  3. Start date: Jun 1, 2024 to Dec 1, 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance.
Trial Details
NCT Number NCT06387667
Lead Sponsor New Valley University
Conditions
(from sponsor)		 Immunocompromised ICU Patients With Respiratory Tract Infections
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov